High-RiskPhase 2NCT04730232
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
A Phase 2 study testing Tislelizumab and Nab-paclitaxel in people with High-Risk and Non-Muscle Invasive Bladder Urothelial Carcinoma, run by Tianjin Medical University Second Hospital at 1 site in China.
Trial summary
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- High-Risk, Non-Muscle Invasive Bladder Urothelial Carcinoma
- What is being tested?
- Tislelizumab and Nab-paclitaxel
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 63 participants
- Where
- 1 siteChina
- Study dates
- 27 Dec 2020to Jul 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Willing and able to provide written informed consent;
- Ability to comply with the protocol;
- Age ≥ 18 years;
- High-risk non-muscle-invasive urothelial carcinoma or high-risk non-muscle-invasive urothelial carcinoma as the main pathological component > 50%, difined as following:
- T1 b. High-grade Ta c.Carcinoma in situ(CIS);
- Multi-point biopsy of bladder shows there are more than 2 section and over 3 points of pathological specimens are diagnosed as above, meanwhile, the tumor has to be diagnosed as not completely resectable by at least 2 senior urologist;
Show all 12Show fewer
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2;
- Agreed to provide tissue examination samples (for detection of PD-L1 expression, tumor mutation load, IHC, detection of DNA and RNA, etc;)
- Organ function level must meet the following requirements:
- Hematological indexes: neutrophil count >= 1.5x10^9/L, platelet count >= 80x10^9/L, hemoglobin >= 6.0 g/dl (can be maintained by blood transfusion);
- Liver function: total bilirubin <=1.5 ULN, alanine aminotransferase and aspartate aminotransferase <=2.5 ULN;
- The subjects volunteered to join the study, signed informed consent, and had good compliance with follow-up;
Who cannot join
- Receive live attenuated vaccine within 4 weeks before treatment or during the study period;
- Active, known or suspected autoimmune diseases;
- History of primary immunodeficiency;
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
- Pregnant or lactating female patients;
- Untreated acute or chronic active hepatitis B or hepatitis C infection. Under the condition of monitoring the virus copy number of patients receiving antiviral treatment, doctors can judge whether they are in line with the patients' individual conditions;
Show all 17Show fewer
- Prior use of immunosuppressive drugs within 4 weeks prior to the start of treatment, excluding nasal and inhaled corticosteroids or physiological doses of systemic steroids (i.e. not more than 10 mg / day prednisolone or other corticosteroids with the same physiological dose);
- Known or suspected allergy to tislelizumab and albumin paclitaxel;
- Have a clear history of active tuberculosis;
- Received PD-1 / PD-L1 / CTLA-4 antibody or other immunotherapy in the past;
- Participating in other clinical researchers;
- Men with reproductive capacity or women who are likely to become pregnant do not take reliable contraceptive measures;
- Uncontrolled concurrent diseases, including but not limited to:
- HIV infected (HIV antibody positive);
- Severe infection in active stage or poorly controlled;
- Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [i.e. hypertension greater than or equal to CTCAE grade 2 after drug treatment]);
- Patients with active bleeding or new thrombotic disease.
Trial locations and contacts
1 site in 1 country.
China1 site, 1 recruiting
- Recruiting
Tianjin Medical University Second Hospital
Tianjin, Tianjin Municipality, 300211
Hailong Hu, +86-13662096232, hhllove2004@163.com
About this study
Official title: An Open Label, Single-arm, Phase 2 Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 4 treatment cycles over 12 weeks followed by transurethral resection biopsy.
- Being tested
- Tislelizumab, Nab-paclitaxel
- Keywords
- Tislelizumab, Nab-Paclitaxel
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TislelizumabDrug
Also called BGB-A317
Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles.
Nab-paclitaxelDrug
Nab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles.
| Study group | Role | What they receive |
|---|---|---|
| Tislelizumab and Nab-Paclitaxel | Experimental | Tislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy. Receives: Drug: Tislelizumab; Drug: Nab-paclitaxel |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complete Response (CR) Rate for tilelizumab combined with nab-paclitaxel
Measured: At the time of transurethral resection biopsy (within 9 or 12 weeks of the first dose of tislelizumab)
Secondary outcomes (3)
Cystectomy-Free Survival (CFS)
defined from D1 of treatment until cystectomy.
Measured: up to 3 years
Duration of Response (DOR)
Measured: up to 3 years
Number of adverse events and severity by grade (CTCAE)
Safety and toxicity will be characterized according to the reported adverse event (AE) profile using NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0, as well as a patient questionnaire derived from the Patient Reported Outcomes (PRO)-CTCAE and Patient Reported Outcomes Measurement Information System (PROMIS).
Measured: 12 weeks of treatment plus 30 days for toxicity followup
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jan 2021
- Study start27 Dec 2020
- Primary completionFeb 2024 (estimated)
- Study completionJul 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for High-RiskStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 63 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tianjin Medical University Second Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Hailong Hu, MD,PhD, Principal investigator, Tianjin Medical University Second Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04730232
- Sponsor's protocol ID
- Truce-02
- Status last verified
- Oct 2021
- First submitted
- 25 Jan 2021
- Last updated
- 29 Oct 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Chen H, Lin Y, Xue Z, Qie Y, Wu Z, Liu K, Huang S, Jia K, Yang S, Zhang Z, Li P, Li X, Liu L, Shen C, Hu H. Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes. Front Immunol. 2026 Aug 10;17:1929760. doi: 10.3389/fimmu.2026.1929760. eCollection 2026.
PubMed 42639047
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open Label, Single-arm, Phase 2 Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
- ClinicalTrials.gov ID
- NCT04730232
- Acronym / sponsor ID
- Truce-02
- Keywords
- Tislelizumab, Nab-Paclitaxel
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 63 participants (estimated)
- Lead sponsor
- Tianjin Medical University Second HospitalUniversity, hospital or other
- Study start
- 27 Dec 2020 (actual)
- Primary completion
- Feb 2024 (estimated)
- Study completion
- Jul 2024 (estimated)
- First posted
- 29 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not completely resectable. Patients will receive treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 4 treatment cycles over 12 weeks followed by transurethral resection biopsy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Tislelizumab and Nab-Paclitaxel | Experimental | Drug: Tislelizumab, Drug: Nab-paclitaxelTislelizumab 200mg IV on day 1 in combination with nab-paclitaxel 200mg IV on day 2 every 3 weeks for 3 or 4 cycles followed by transurethral resection biopsy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Willing and able to provide written informed consent;
- Ability to comply with the protocol;
- Age ≥ 18 years;
- High-risk non-muscle-invasive urothelial carcinoma or high-risk non-muscle-invasive urothelial carcinoma as the main pathological component > 50%, difined as following:
- Multi-point biopsy of bladder shows there are more than 2 section and over 3 points of pathological specimens are diagnosed as above, meanwhile, the tumor has to be diagnosed as not completely resectable by at least 2 senior urologist;
Key exclusion criteria (17 listed)
- Receive live attenuated vaccine within 4 weeks before treatment or during the study period;
- Active, known or suspected autoimmune diseases;
- History of primary immunodeficiency;
- Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
- Pregnant or lactating female patients;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TislelizumabAlso: BGB-A317Tislelizumab 200mg will be administered on Day 1 of each cycle for 4 treatment cycles. | Drug | Tislelizumab and Nab-Paclitaxel |
| Nab-paclitaxelNab-paclitaxel 200mg will be administered on Day 2 of each cycle for 4 treatment cycles. | Drug | Tislelizumab and Nab-Paclitaxel |
Primary outcome
Complete Response (CR) Rate for tilelizumab combined with nab-paclitaxel
Time frame: At the time of transurethral resection biopsy (within 9 or 12 weeks of the first dose of tislelizumab)
3 secondary outcomes
Cystectomy-Free Survival (CFS)
Time frame: up to 3 years
Duration of Response (DOR)
Time frame: up to 3 years
Number of adverse events and severity by grade (CTCAE)
Time frame: 12 weeks of treatment plus 30 days for toxicity followup
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2021.
- Derived from this study: PubMed 42639047Chen H, Lin Y, Xue Z, Qie Y, Wu Z, Liu K, Huang S, Jia K, Yang S, Zhang Z, Li P, Li X, Liu L, Shen C, Hu H. Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes. Front Immunol. 2026 Aug 10;17:1929760. doi: 10.3389/fimmu.2026.1929760. eCollection 2026.
Related trials for High-Risk
RecruitingObservational study
AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM)
Cardiomyopathies, Cardiac Arrest
Active, not recruitingPhase 1/2
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
Multiple Myeloma
Not yet recruiting
A Pre-post Study of a Lethal Means Safety Planning Intervention for Youth at Elevated Suicide Risk in the Emergency Department
Suicidal Ideas, Suicidal Ideation
RecruitingPhase 2
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hailong Hu, MD,PhD principal investigator
Tianjin Medical University Second Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Tislelizumab and Nab-paclitaxel in people with High-Risk and Non-Muscle Invasive Bladder Urothelial Carcinoma, run by Tianjin Medical University Second Hospital at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 29 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Hailong Hu, MD,PhD (+86-13662096232, hhllove2004@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complete Response (CR) Rate for tilelizumab combined with nab-paclitaxel (time frame: At the time of transurethral resection biopsy (within 9 or 12 weeks of the first dose of tislelizumab)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04730232, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2021.